
Metabolic Disorders
Denosumab increases bone mineral density in male patients with low BMD
This report has been verified
by one or more authors of the
original publication.
J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21
242 male patients with low bone mineral density were randomized to receive treatment with denosumab or a placebo to determine the effect of denosumab on bone mineral density in the male population. After 1 year of treatment, the denosumab group demonstrated a significantly greater increase in bone mineral density than the control group at the lumbar spine, total hip, femoral neck, trochanter, and the one third radius. There was also a significant decrease in serum CTX levels in the denosumab group at 15 days. The two groups did not differ significantly with respect to adverse events.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.